Table 2.
Plasma pharmacokinetics of the different curcumin formulations
| Formulation | Curcumin | AUC (nM.h) median (range) | Cmax (nM) Median (range) |
Tmax (h) |
|---|---|---|---|---|
| Curcumin 600 mg | Unconjugated | n.d. | <LOQ | n.r.∗ |
| Total | 289 (30–481) | 21 (13–44) | 8 | |
| Curcumin 2400 mg | Unconjugated | n.d. | <LOQ | n.r.∗ |
| Total | 897 (122–1475) | 44 (5.9–102) | 4 | |
| Curcumin 2400 mg + piperine 20 mg | Unconjugated | n.d. | <LOQ | n.r.∗ |
| Total | 524 (26–1724) | 35 (12–81) | 8 | |
| Longvida® (625 mg curcumin) | Unconjugated | n.d. | <LOQ | n.r.∗ |
| Total | 271 (124–517) | 15 (5.3–45) | 8 | |
| NovaSOL® (576 mg curcuminoids) | Unconjugated | 32 (13–94) | 15 (6.7–38) | 1 |
| Total | 11590 (3450–22040) | 2780 (1010–4950) | 1.5 |
All samples were analyzed without and with pre-processing with β-glucuronidase to assess the levels of unconjugated and total (conjugated and unconjugated) curcumin in plasma.
n.d., not detected; ∗n.r., not reached; Total, unconjugated plus conjugated curcumin; LOQ, Lowest Limit of Quantification.